Prealbumin content of cerebrospinal fluid and sera in persons with multiple sclerosis

Kržalić, Lj.

doi:10.1016/0009-8981(82)90427-2

Cited by 12 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since cerebral TTR is a major thyroxine (T4) carrier, it is noteworthy to mention that oxidative modifications in CSF TTR are accompanied by a downregulation in the levels of free T4 [ 43 ], suggesting that oxidative posttranslational modifications in the protein alter the capacity to act as a carrier of the hormone. In contrast with the results obtained in the present work, previous studies reported an upregulation, downregulation or no alterations in TTR protein levels in the CSF of patients with MS [ 20 , 23 , 43 – 46 ]. The differential results reflect the diversity of approaches used in previous studies to assess the TTR alterations in the CSF of MS patients and shows the relevance of using methodologies that identify posttranslational modifications of the protein, or those that can distinguish different proteoforms, such as 2D-PAGE.…”

Section: Discussioncontrasting

confidence: 99%

Posttranslational modifications of proteins are key features in the identification of CSF biomarkers of multiple sclerosis

Salazar

Lourenco

Manadas

et al. 2022

J Neuroinflammation

View full text Add to dashboard Cite

Background Multiple sclerosis is an inflammatory and degenerative disease of the central nervous system (CNS) characterized by demyelination and concomitant axonal loss. The lack of a single specific test, and the similarity to other inflammatory diseases of the central nervous system, makes it difficult to have a clear diagnosis of multiple sclerosis. Therefore, laboratory tests that allows a clear and definite diagnosis, as well as to predict the different clinical courses of the disease are of utmost importance. Herein, we compared the cerebrospinal fluid (CSF) proteome of patients with multiple sclerosis (in the relapse–remitting phase of the disease) and other diseases of the CNS (inflammatory and non-inflammatory) aiming at identifying reliable biomarkers of multiple sclerosis. Methods CSF samples from the discovery group were resolved by 2D-gel electrophoresis followed by identification of the protein spots by mass spectrometry. The results were analyzed using univariate (Student’s t test) and multivariate (Hierarchical Cluster Analysis, Principal Component Analysis, Linear Discriminant Analysis) statistical and numerical techniques, to identify a set of protein spots that were differentially expressed in CSF samples from patients with multiple sclerosis when compared with other two groups. Validation of the results was performed in samples from a different set of patients using quantitative (e.g., ELISA) and semi-quantitative (e.g., Western Blot) experimental approaches. Results Analysis of the 2D-gels showed 13 protein spots that were differentially expressed in the three groups of patients: Alpha-1-antichymotrypsin, Prostaglandin-H2-isomerase, Retinol binding protein 4, Transthyretin (TTR), Apolipoprotein E, Gelsolin, Angiotensinogen, Agrin, Serum albumin, Myosin-15, Apolipoprotein B-100 and EF-hand calcium-binding domain—containing protein. ELISA experiments allowed validating part of the results obtained in the proteomics analysis and showed that some of the alterations in the CSF proteome are also mirrored in serum samples from multiple sclerosis patients. CSF of multiple sclerosis patients was characterized by TTR oligomerization, thus highlighting the importance of analyzing posttranslational modifications of the proteome in the identification of novel biomarkers of the disease. Conclusions The model built based on the results obtained upon analysis of the 2D-gels and in the validation phase attained an accuracy of about 80% in distinguishing multiple sclerosis patients and the other two groups.

show abstract

Section: Discussioncontrasting

confidence: 99%

Posttranslational modifications of proteins are key features in the identification of CSF biomarkers of multiple sclerosis

Salazar

Lourenco

Manadas

et al. 2022

J Neuroinflammation

View full text Add to dashboard Cite

show abstract

“…In cerebrospinal fluid, the specific oxidative modification of TTR Cys10 has been associated with demyelinating diseases [80]. The serum TTR content was the same as in healthy persons, as previously reported [81]. Therefore, the not significant difference recorded in this study might suggest an unaltered level of TTR in MS patients' cerebrospinal fluid too.…”

Section: Discussionsupporting

confidence: 78%

Chelation Therapy Associated with Antioxidant Supplementation Can Decrease Oxidative Stress and Inflammation in Multiple Sclerosis: Preliminary Results

et al. 2023

View full text Add to dashboard Cite

An imbalance of oxy-inflammation status has been involved in axonal damage and demyelination in multiple sclerosis (MS). The aim of this study was to investigate the efficacy of an antioxidant treatment (calcium disodium ethylenediaminetetracetic acid—EDTA) chelation therapy associated with a micronutrient complex in MS patients. A total of 20 MS patients and 20 healthy subjects, enrolled as a control group (CTR), were recruited. We measured the plasma ROS production and total antioxidant capacity (TAC) by a direct assessment using Electron Paramagnetic Resonance; activities of the antioxidant system (thiols’ redox status and enzymes); and the urinary presence of biomarkers of oxidative stress by immunoenzymatic assays. We also evaluated the levels of inflammation by plasmatic cytokines (TNFα, IL-1β, and IL-6) and assessed the sICAM levels, as well as the nitric oxide (NO) catabolism and transthyretin (TTR) concentration. Comparing CTR and MS, in the latter ROS production, oxidative damage, inflammatory biomarkers, and NO metabolite concentrations results were significantly higher, while TAC was significantly lower. Treatment in MS induced significant (p < 0.05) down-regulating of pro-inflammatory sICAM1, TNF-α, IL6, as well as biomarkers of lipid peroxidation and DNA damage production. The protective effect exhibited may occur by decreasing ROS production and increasing antioxidant capacity, turning into a more reduced thiols’ status.

show abstract

“…Although the mean level of prealbumin in CSF of MS patients was found to be twice that of controls, no significant difference was found in the serum concentration (50).…”

Section: A Zincmentioning

confidence: 59%

Abnormalities of serum and plasma components in patients with multiple sclerosis

Ford

1985

Clinical Biochemistry

View full text Add to dashboard Cite

Qualitative and quantitative abnormalities in protein and non-protein components of serum and plasma in patients with multiple sclerosis have been the subjects of numerous reports. In this review many of the more recent observations are documented and evaluated. It is concluded that at present the welter of information that has been gathered does not contribute in any major, coherent way to our understanding of the etiology or pathogenesis of the disorder. Several of the abnormalities that have been observed may be future candidates for biochemical markers for multiple sclerosis; at present none is sufficiently reliable, distinctive or easily performed to warrant the status of a useful diagnostic or prognostic test.

show abstract

Prealbumin content of cerebrospinal fluid and sera in persons with multiple sclerosis

Cited by 12 publications

References 6 publications

Posttranslational modifications of proteins are key features in the identification of CSF biomarkers of multiple sclerosis

Posttranslational modifications of proteins are key features in the identification of CSF biomarkers of multiple sclerosis

Chelation Therapy Associated with Antioxidant Supplementation Can Decrease Oxidative Stress and Inflammation in Multiple Sclerosis: Preliminary Results

Abnormalities of serum and plasma components in patients with multiple sclerosis

Contact Info

Product

Resources

About